CSIMarket
 
Protara Therapeutics Inc  (NASDAQ: TARA)
Other Ticker:  
 
 
Price: $4.9900 $-0.12 -2.348%
Day's High: $5.1 Week Perf: 10.89 %
Day's Low: $ 4.90 30 Day Perf: -18.73 %
Volume (M): 180 52 Wk High: $ 10.48
Volume (M$): $ 899 52 Wk Avg: $3.11
Open: $5.10 52 Wk Low: $1.60



 Market Capitalization (Millions $) 111
 Shares Outstanding (Millions) 22
 Employees 35
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -42
 Cash Flow (TTM) (Millions $) 15
 Capital Exp. (TTM) (Millions $) 0

Protara Therapeutics Inc
Protara Therapeutics Inc is a biopharmaceutical company that focuses on developing and commercializing novel therapies to treat rare and specialty diseases. The company is dedicated to improving the lives of patients by providing innovative treatment options. Protara Therapeutics Inc utilizes a targeted approach to identify and develop drug candidates, with a particular emphasis on rare diseases with significant unmet medical needs. The company's goal is to bring these therapies to market and make a meaningful impact on patient outcomes.


   Company Address: 345 Park Avenue South New York 10010 NY
   Company Phone Number: 844-0337   Stock Exchange / Ticker: NASDAQ TARA


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
AMGN        5.54% 
BIIB   -0.55%    
CHRS   -11.11%    
EXEL        1.88% 
HALO        2.14% 
RGNX        6.71% 
• View Complete Report
   



Management Announcement

Protara Therapeutics Sees Stock Surge Following Positive Trial Results, Faces Financial Hurdles as It Aims for 2025 Milestones,

Published Mon, Jan 13 2025 1:00 PM UTC

Protara Therapeutics Reports Promising Trial Results Amidst Financial ChallengesProtara Therapeutics Inc., a biopharmaceutical company focused on advancing therapies for rare diseases, has recently highlighted significant updates and anticipated milestones for 2025. Notably, the company reported positive six-month data from the ADVANCED-2 trial of TARA-002 in patients with n...

Clinical Study

Protara Therapeutics Advances NMIBC Fight with Promising TARA-002 Data at SUO Meeting,

Published Fri, Nov 15 2024 10:52 PM UTC

Protara Therapeutics Unveils Promising Interim Results for TARA-002 in NMIBC at Prestigious Oncology Meeting Amidst the gathering of leading experts and trailblazers at the 25th Annual Meeting of the Society of Urologic Oncology (SUO) in Dallas, Texas, Protara Therapeutics, Inc. (Nasdaq: TARA) is set to make a compelling presentation regarding their latest findings on TARA-0...

Clinical Study

Protara Therapeutics Reveals Critical THRIVE-1 Study Findings on Choline Deficiency and Liver Injury at ESPEN 2024,

Published Mon, Sep 9 2024 12:00 PM UTC

Protara Therapeutics Presents Groundbreaking Insights from THRIVE-1 Study on Choline Deficiency and Liver Injury in Patients Dependent on Parenteral Support at ESPEN Conference NEW YORK, Sept. 09, 2024 - Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company at the forefront of developing transformative therapies for cancer and rare diseases, has unveiled key fi...

Shares

Protara Therapeutics Grants Inducement Stock Options to New VP Lisa Schlesinger

Published Mon, Jun 24 2024 9:07 PM UTC


In a recent press release, Protara Therapeutics, Inc. has announced the grant of inducement non-qualified stock options to Lisa Schlesinger, the newly appointed Vice President, Head of New Product Development and Market Access. This move comes as Protara continues to focus on developing transformative therapies for the treatment of cancer and rare diseases.
The gran...

Clinical Study

Unveiling IV Choline Chloride: A Potential Game-Changer for Parenteral Nutrition-Dependent Patients

Published Fri, Apr 5 2024 12:02 PM UTC

Protara Therapeutics, a pioneering clinical-stage biopharmaceutical company, has recently gained endorsement from the U.S. Food and Drug Administration (FDA) for its investigational intravenous (IV) Choline Chloride. This groundbreaking treatment serves as a phospholipid replacement substrate and holds promising potential for patients reliant on parenteral nutrition (PN) but...










Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com